UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 1-11083

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	04-2695240
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234

        (Address of Principal Executive Offices)                         (Zip Code)

508 683-4000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	BSX	New York Stock Exchange
0.625% Senior Notes due 2027	BSX27	New York Stock Exchange
5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share	BSX PR A	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☑	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

The number of shares outstanding of Common Stock, $0.01 par value per share, as of July 30, 2021 was 1,423,852,648.

TABLE OF CONTENTS

		Page No.
PART I	FINANCIAL INFORMATION	3
ITEM 1.	Consolidated Financial Statements	3
	Consolidated Statements of Operations (Unaudited)	3
	Consolidated Statements of Comprehensive Income (Loss) (Unaudited)	4
	Consolidated Balance Sheets (Unaudited as of June 30, 2021)	5
	Consolidated Statements of Stockholders' Equity (Unaudited)	6
	Consolidated Statements of Cash Flows (Unaudited)	7
	Notes to the Consolidated Financial Statements (Unaudited)	9
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	38
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	59
ITEM 4.	Controls and Procedures	60
PART II	OTHER INFORMATION	61
ITEM 1.	Legal Proceedings	61
ITEM 1A.	Risk Factors	61
ITEM 6.	Exhibits	61
SIGNATURE		62

2

PART I

FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Months Ended June 30,				Six Months Ended June 30,
(in millions, except per share data)	2021		2020		2021		2020
Net sales	$	3,077	$	2,003	$	5,829	$	4,546
Cost of products sold	945		791		1,839		1,596
Gross profit	2,132		1,212		3,990		2,950
Operating expenses:
Selling, general and administrative expenses	1,121		798		2,139		1,776
Research and development expenses	298		242		574		542
Royalty expense	12		8		24		20
Amortization expense	180		197		365		398
Intangible asset impairment charges	45		34		45		233
Contingent consideration net expense (benefit)	(85)		—		(91)		(108)
Restructuring net charges (credits)	3		3		8		13
Litigation-related net charges (credits)	298		—		302		—
Gain on disposal of business	(2)		—		(9)		—
	1,870		1,283		3,358		2,875
Operating income (loss)	262		(71)		632		75
Other income (expense):
Interest expense	(86)		(91)		(168)		(179)
Other, net	(26)		(18)		11		(54)
Income (loss) before income taxes	149		(181)		474		(159)
Income tax expense (benefit)	(37)		(33)		(53)		(22)
Net income (loss)	186		(147)		527		(137)
Preferred stock dividends	(14)		(5)		(28)		(5)
Net income (loss) available to common stockholders	$	172	$	(153)	$	500	$	(142)
Net income (loss) per common share — basic	$	0.12	$	(0.11)	$	0.35	$	(0.10)
Net income (loss) per common share — assuming dilution	$	0.12	$	(0.11)	$	0.35	$	(0.10)
Weighted-average shares outstanding
Basic	1,421.3		1,410.9		1,420.0		1,404.1
Assuming dilution	1,432.5		1,410.9		1,431.7		1,404.1

See notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

3

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

	Three Months Ended June 30,				Six Months Ended June 30,
(in millions)	2021		2020		2021		2020
Net income (loss)	$	186	$	(147)	$	527	$	(137)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	2		(11)		(81)		(187)
Net change in derivative financial instruments	(18)		(26)		111		48
Net change in defined benefit pensions and other items	—		—		1		—
Total other comprehensive income (loss)	(16)		(37)		30		(139)
Total comprehensive income (loss)	$	170	$	(185)	$	558	$	(276)

See notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

4

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	As of
(in millions, except share and per share data)	June 30, 2021		December 31, 2020
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	2,675	$	1,734
Trade accounts receivable, net	1,675		1,531
Inventories	1,430		1,351
Prepaid income taxes	202		194
Assets held for sale	—		1,133
Other current assets	777		751
Total current assets	6,758		6,694
Property, plant and equipment, net	2,082		2,084
Goodwill	10,874		9,951
Other intangible assets, net	5,788		5,917
Deferred tax assets	4,036		4,210
Other long-term assets	1,629		1,921
TOTAL ASSETS	$	31,168	$	30,777
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current debt obligations	$	262	$	13
Accounts payable	689		513
Accrued expenses	2,442		2,197
Other current liabilities	680		958
Total current liabilities	4,073		3,681
Long-term debt	8,847		9,130
Deferred income taxes	115		330
Other long-term liabilities	2,190		2,309
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of June 30, 2021 and December 31, 2020	—		—
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,685,006,608 shares as of June 30, 2021 and 1,679,911,918 shares as of December 31, 2020	17		17
Treasury stock, at cost - 263,289,848 shares as of June 30, 2021 and December 31, 2020	(2,251)		(2,251)
Additional paid-in capital	19,817		19,732
Accumulated deficit	(1,878)		(2,378)
Accumulated other comprehensive income (loss), net of tax	237		207
Total stockholders’ equity	15,942		15,326
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	31,168	$	30,777

See notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

5

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)

	Preferred Stock			Common Stock			Treasury Stock		Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss), Net of Tax
(in millions, except share data)	Shares Issued	Par Value		Shares Issued	Par Value
As of December 31, 2019	—	$	—	1,642,488,911	$	16	$	(1,717)	$	17,561	$	(2,253)	$	270
Net income (loss)											11
Cumulative effect adjustment for adoption of ASU 2016-13											(10)
Total other comprehensive income (loss)													(101)
Stock-based compensation				4,388,331					28
As of March 31, 2020	—	$	—	1,646,877,242	$	16	$	(1,717)	$	17,589	$	(2,252)	$	168
Net income (loss)											(147)
Total other comprehensive income (loss)													(37)
Preferred stock issuance	10,062,500	—							975
Common stock issuance				29,382,500	—				975
Preferred stock dividends											(5)
Stock-based compensation				493,824					50
As of June 30, 2020	10,062,500	$	—	1,676,753,566	$	17	$	(1,717)	$	19,590	$	(2,405)	$	131
Net income (loss)											(155)
Total other comprehensive income (loss)													20
Preferred stock dividends											(14)
Stock-based compensation				2,674,643					97
As of September 30, 2020	10,062,500	$	—	1,679,428,209	$	17	$	(1,717)	$	19,687	$	(2,574)	$	151
Net income (loss)											210
Total other comprehensive income (loss)													56
Preferred stock dividends											(14)
Repurchase of common stock							(535)
Stock-based compensation				483,709					45
As of December 31, 2020	10,062,500	$	—	1,679,911,918	$	17	$	(2,251)	$	19,732	$	(2,378)	$	207
Net income (loss)											341
Total other comprehensive income (loss)													47
Preferred stock dividends											(14)
Stock-based compensation				3,949,308					19
As of March 31, 2021	10,062,500	$	—	1,683,861,226	$	17	$	(2,251)	$	19,750	$	(2,050)	$	254
Net income (loss)											186
Total other comprehensive income (loss)													(16)
Preferred stock dividends											(14)
Stock-based compensation				1,145,382					66
As of June 30, 2021	10,062,500	—		1,685,006,608	$	17	$	(2,251)	$	19,817	$	(1,878)	$	237

See notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

6

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Six Months Ended June 30,
(in millions)	2021		2020
Net income (loss)	$	527	$	(137)
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Gain on disposal of businesses	(8)		—
Depreciation and amortization	531		552
Deferred and prepaid income taxes	(88)		15
Stock-based compensation expense	94		88
Intangible asset impairment charges	45		233
Net loss (gain) on investments and notes receivable	(22)		34
Contingent consideration net expense (benefit)	(91)		(108)
Inventory step-up amortization	8		30
Foreign exchange (gain) loss	9		12
Other, net	26		35
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable	(145)		365
Inventories	(100)		(36)
Other assets	(200)		(179)
Accounts payable and accrued expenses	187		(531)
Other liabilities	153		(181)
Cash provided by (used for) operating activities	927		192
Purchases of property, plant and equipment	(181)		(168)
Proceeds from sale of property, plant and equipment	7		4
Payments for acquisitions of businesses, net of cash acquired	(706)		(3)
Proceeds from royalty rights	43		45
Payments for investments and acquisitions of certain technologies	(30)		(29)
Proceeds from sale of investments	122		—
Proceeds from disposal of businesses	801		15
Proceeds from settlements of hedge contracts	15		—
Cash provided by (used for) investing activities	71		(135)
Payment of contingent consideration previously established in purchase accounting	(14)		(38)
Payments for royalty rights	(42)		(52)
Payments on short-term borrowings	—		(2,700)
Proceeds from short-term borrowings, net of debt issuance costs	—		2,245
Net increase (decrease) in commercial paper	—		(714)
Payments on borrowings from credit facilities	—		(1,919)
Proceeds from borrowings on credit facilities	—		1,916
Payments on long-term borrowings and debt extinguishment costs	—		(1,000)
Proceeds from long-term borrowings, net of debt issuance costs	—		1,683
Cash dividends paid on preferred stock	(28)		—
Net proceeds from issuance of preferred stock in connection with public offering	—		975
Net proceeds from issuance of common stock in connection with public offering	—		975
Cash used to net share settle employee equity awards	(47)		(57)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans	38		48
Cash provided by (used for) financing activities	(93)		1,361
Effect of foreign exchange rates on cash	(2)		(9)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	903		1,409
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	1,995		607
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$	2,898	$	2,016

See notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

7

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(SUPPLEMENTAL INFORMATION)

	Six Months Ended June 30,
(in millions)	2021		2020
Supplemental Information
Stock-based compensation expense	$	94	$	88
Fair value of contingent consideration recorded in purchase accounting	221		—
Non-cash impact of transferred royalty rights	(43)		(45)

	As of June 30,
Reconciliation to amounts in the unaudited consolidated balance sheets:	2021		2020
Cash and cash equivalents	$	2,675	$	1,724
Restricted cash and restricted cash equivalents included in Other current assets	167		245
Restricted cash equivalents included in Other long-term assets	57		46
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$	2,898	$	2,016

See notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.

8

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A – BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Subsequent Events

We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly. Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note B – Acquisitions, Divestitures and Strategic Investments, Note H – Commitments and Contingencies and Note I – Stockholders' Equity for further details.

NOTE B – ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We completed one acquisition and one divestiture in the first six months of 2021 and did not complete any significant acquisitions or divestitures during the first six months of 2020. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.

On March 3, 2021, we announced our entry into a definitive agreement to acquire the global surgical business of Lumenis LTD. (Lumenis), a privately-held company that develops and commercializes energy-based medical solutions, for an upfront cash payment of approximately $1.070 billion subject to closing adjustments. The global surgical business of Lumenis includes innovative laser systems, fibers, and accessories used for urology and otolaryngology procedures. The acquisition is expected to close during the second half of 2021, subject to customary closing conditions. Following the closing of the acquisition, we plan to integrate the Lumenis business into our Urology and Pelvic Health division.

2021 Acquisitions

On March 1, 2021, we completed the acquisition of Preventice Solutions, Inc. (Preventice), a privately-held company which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors, to cardiac event monitors and mobile cardiac telemetry. The transaction consisted of an upfront cash payment of $925 million and up to an additional $300 million in a potential commercial milestone payment. We have been an investor in Preventice since 2015 and held an equity stake of approximately 22 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the allocation of the purchase price according to priority of equity interests, which resulted in a $195 million gain recognized within Other, net in the first quarter of 2021. The transaction price for the remaining stake consisted of an upfront cash payment of $706 million, net of cash acquired, and up to approximately $230 million in an additional future revenue-based payment. The Preventice business is being managed by our Cardiac Rhythm Management division.

9

On August 6, 2021, we completed our acquisition of the remaining shares of Farapulse, Inc. (Farapulse), a privately-held company that has developed a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias in which we previously held an equity stake of approximately 27 percent. The transaction price consists of $450 million upfront, or approximately $295 million after adjustments for our prior equity stake, debt and other closing adjustments; up to $125 million upon achievement of certain clinical and regulatory milestones, or $92 million for the portion not previously owned; and additional revenue-based payments over the next three years. The valuation studies necessary to determine the fair value of the various purchase price components are currently in process. Once completed, we will remeasure the fair value of our previously held equity interest and recognize a gain of at least $150 million within Other income (expense) during the third quarter of 2021. The Farapulse business will be integrated into our Electrophysiology division.

Purchase Price Allocation

The preliminary purchase price for acquisitions completed during the first six months of 2021 was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations.

(in millions)
Payment for acquisition, net of cash acquired	$	706
Fair value of contingent consideration	221
Fair value of prior interest	269
	$	1,197

The preliminary purchase price allocation for acquisitions completed during the first six months of 2021 was comprised of the following components:

(in millions)
Goodwill	$	926
Amortizable intangible assets	237
Other assets acquired	65
Liabilities assumed	(32)
	$	1,197

We allocated a portion of the preliminary purchase price for acquisitions completed during the first six months of 2021 to the specific intangible asset categories as follows:

	Amount Assigned (in millions)		Weighted Average Amortization Period (in years)	Risk-Adjusted Discount Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related	$	215	9	10%
Other intangible assets	22		8	10%
	$	237

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies and is not deductible for tax purposes.

2021 Divestiture

On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800

10

million, subject to certain adjustments including cash on hand at the closing of the transaction. The agreement included the transfer of five facilities and approximately 280 employees globally.

We classified the assets and liabilities of the Specialty Pharmaceuticals business (disposal group) as held for sale within our consolidated balance sheet as of December 31, 2020 at their respective carrying values, which approximated fair value, less costs to sell. Assets within the disposal group are presented within Assets held for sale and liabilities are presented within Other current liabilities within our consolidated balance sheet as of December 31, 2020. Refer to Note C – Assets and Liabilities Held for Sale to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information. In the second quarter and first six months of 2021, we recognized a Gain on disposal of business associated with the transaction of $2 million and $9 million respectively, within our accompanying unaudited consolidated statements of operations.

Contingent Consideration

Changes in the fair value of our contingent consideration liability during the first six months of 2021 were as follows:

(in millions)
Balance as of December 31, 2020	$	196
Amount recorded related to current year acquisitions	221
Contingent consideration net expense (benefit)	(91)
Contingent consideration payments	(14)
Balance as of June 30, 2021	$	312

As of June 30, 2021, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was $751 million, which includes amounts related to our recent acquisition of Preventice. Refer to Note B – Acquisitions and Strategic Investments to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information. In the second quarter of 2021 we recorded a contingent consideration net benefit of $85 million. The benefit related to certain prior acquisitions for which we reduced the probability of achievement of associated revenue and/or regulatory milestones upon which payment is conditioned.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:

Contingent Consideration Liability	Fair Value as of June 30, 2021	Valuation Technique	Unobservable Input	Range				Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones	$22 million	Discounted Cash Flow	Discount Rate	2%				2%
			Probability of Payment	20%				20%
			Projected Year of Payment	2027				2027
Revenue-based Payments	$290 million	Discounted Cash Flow	Discount Rate	4	%	-	14%	6%
			Probability of Payment	80	%	-	100%	100%
			Projected Year of Payment	2021		-	2024	2022

(1)    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to research and development (R&D), commercialization-based and revenue-based milestones are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of June 30, 2021.

11

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:

	As of
(in millions)	June 30, 2021		December 31, 2020
Equity method investments	$	264	$	319
Measurement alternative investments(1)	175		183
Publicly-held equity securities(2)	176		414
Notes receivable	—		2
	$	616	$	918

(1)    Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.

(2)    Publicly-held equity securities are measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying unaudited consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

In the second quarter and first six months of 2021, we recorded losses of $8 million and $154 million, respectively, on our investment in Pulmonx Corporation presented in Other, net associated with the partial disposition of our ownership and remeasurement of our remaining investment to fair value based on observable market prices. On March 1, 2021, we completed our acquisition of Preventice, in which we previously held an equity interest of approximately 22 percent. In addition, on August 6, 2021, we completed the acquisition of the remaining shares of Farapulse, in which we previously held an equity stake of approximately 27 percent. As of June 30, 2021, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $314 million, which represents amortizable intangible assets, in-process research and development (IPR&D), goodwill and deferred tax liabilities.

NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:

	As of June 30, 2021				As of December 31, 2020
(in millions)	Gross Carrying Amount		Accumulated Amortization/ Write-offs(1)		Gross Carrying Amount		Accumulated Amortization/ Write-offs
Technology-related	$	11,284	$	(6,475)	$	11,059	$	(6,179)
Patents	497		(397)		511		(407)
Other intangible assets	1,826		(1,278)		1,775		(1,220)
Amortizable intangible assets	$	13,607	$	(8,150)	$	13,345	$	(7,806)
Goodwill	$	20,774	$	(9,900)	$	19,924	$	(9,973)
IPR&D	$	210			$	257
Technology-related	120				120
Indefinite-lived intangible assets	$	330			$	377

(1)    In the fourth quarter of 2020, we recorded goodwill impairment charges of $73 million related to the Specialty Pharmaceuticals business and classified the remaining assets and liabilities as held for sale as of December 31, 2020. On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. The goodwill impairment charges of $73 million related to the Specialty Pharmaceuticals business are no longer presented within accumulated write-offs above as of June 30, 2021.

The increase in our balance of goodwill and intangible assets is primarily related to our acquisition of Preventice in the first quarter of 2021.

12

Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region.

The following represents our goodwill balance by global reportable segment:

(in millions)	MedSurg		Rhythm and Neuro		Cardiovascular		Total
As of December 31, 2020	$	2,059	$	2,194	$	5,697	$	9,951
Impact of foreign currency fluctuations and other changes in carrying amount	(2)		—		1		(2)
Goodwill acquired	—		926		—		926
As of June 30, 2021	$	2,057	$	3,120	$	5,698	$	10,874

Prior to the divestiture on March 1, 2021, we presented the Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.

Goodwill and Intangible Asset Impairments

We did not record any goodwill impairment charges in the second quarter or first six months of 2021 or 2020. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component.

In the second quarter of 2021, we performed our annual goodwill impairment test for all of our reporting units using the quantitative approach described in FASB ASC Topic 350, Intangibles - Goodwill and Other (FASB ASC Topic 350). We identified the following reporting units in our 2021 annual goodwill impairment test: Interventional Cardiology, Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health and Neuromodulation. We aggregated the Cardiac Rhythm Management and Electrophysiology reporting units, components of the Rhythm Management operating segment, based on the criteria prescribed in FASB ASC Topic 350. We determined that the fair value of each reporting unit exceeded its carrying value and concluded that goodwill was not impaired or at risk of impairment.

We recorded Intangible asset impairment charges of $45 million in the second quarter and first six months of 2021, $34 million in the second quarter of 2020 and $233 million in the first six months of 2020. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. During the second quarter of 2021, we determined it was more likely than not that one of our indefinite-lived intangible assets was impaired based on our qualitative assessment of impairment indicators. We tested the intangible asset for recoverability and recorded an impairment charge associated with incremental time and cost to complete the associated in-process research and development (IPR&D) project.

The impairment charges recorded in the first six months of 2020 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of nVision. These charges were recorded as a result of management’s decision to change commercial launch plans or discontinue certain R&D programs based on cost to complete, time to market, overall economic viability or, specific to nVision, our understanding of the clinical evidence necessary to commercialize the technology.

Refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.

13

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments

Risk Management Strategy

Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecasted intercompany and third-party transactions, and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in Euro, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our accompanying unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold in our accompanying unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated other comprehensive income (loss), net of tax (AOCI) to earnings at that time.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. For these derivative instruments, we elected to use the spot method to assess hedge effectiveness. We also elected to exclude the spot-forward difference, referred to as the excluded component, from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. As such, we defer recognition of foreign currency gains and losses within the Foreign currency translation adjustment (CTA) component of OCI, and we reclassify amortization of the excluded component from AOCI to current period earnings within Interest expense in our accompanying unaudited consolidated statements of operations.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro. As of June 30, 2021 and December 31, 2020, we designated as a net investment hedge a portion of our €900 million in aggregate principal amount of 0.625% senior notes issued in November 2019 and due in 2027. For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains

14

and losses within the CTA component of OCI. We reclassify these gains and losses to current period earnings within Other, net in our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships under FASB ASC Topic 815 as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net in our accompanying unaudited consolidated statements of operations.

Interest Rate Hedging Instruments

Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of June 30, 2021 and December 31, 2020. Prior to 2020, we terminated interest rate derivative instruments that were designated as cash flow hedges and are continuing to recognize the amortization of the gains or losses originally recorded within AOCI to earnings as a component of Interest expense over the same period that the hedged item affects earnings, provided the hedge relationship remains effective. If we determine the hedge relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the amount of gains or losses from AOCI to earnings at that time.

In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs. The balance of the deferred amounts on our terminated cash flow hedges within AOCI was a $27 million loss as of June 30, 2021 and a $29 million loss as of December 31, 2020. We recognized immaterial gains and losses in Interest expense relating to the amortization of our terminated cash flow hedges in the current and prior periods.

We had